Lv41
480 积分 2024-09-23 加入
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
3小时前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
3小时前
已完结
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
4小时前
已完结
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
7小时前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
20天前
已完结
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial
23天前
已完结
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
23天前
已完结
Long-term outcomes of IgA nephropathy in China
1个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
1个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
